Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma
Submission of Orphan Drug designated valemetostat based on pivotal phase 2 trial in patients with…
4 years ago
Wire Stories
Armis Selects Radware to Deliver Cloud Security for AWS
Improves visibility, governance, and threat detection across its cloud environment MAHWAH, N.J., Dec. 28, 2021…
4 years ago
CHTF 2021 Opens in Shenzhen, China to Promote High Quality Development, Build a New Development Pattern
SHENZHEN, China--(BUSINESS WIRE)--#5G--The 23rd China Hi-Tech Fair (CHTF 2021) opened in Shenzhen, China on December…
4 years ago
Options Achieves VMware Cloud Verified Status in NY5
NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Options Technology, the leading Capital Markets services provider,…
4 years ago
Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of…
4 years ago
Nanboya to Start Painting and Wall Hanging Purchases in Singapore!
Purchasing Brand Expands Overseas Antiques and Arts Business SINGAPORE--(BUSINESS WIRE)--#antique--Valuence International Singapore Pte. Ltd. (Singapore;…
4 years ago
AG&P Pratham Kicks-Off Construction of Its Second Liquefied and Compressed Natural Gas (LCNG) Station in Andhra Pradesh
KADAPA, India--(BUSINESS WIRE)--AG&P Pratham in India, the City Gas Distribution (CGD) arm of Singapore-based AG&P…
4 years ago
Global Science City Dialogue Highlights Role of Science Cities in Fostering International Innovation and Collaboration
AMSTERDAM--(BUSINESS WIRE)--#CSTB--Representatives from science and technology parks around the world took part in the Global…
4 years ago
RoboSense Receives BYD’s Strategic Investment and Becomes an Engaged Participant of the Auto Industry
Upgraded partnership to accelerate the global mass production and implementation of smart vehicles SHENZHEN, China--(BUSINESS…
4 years ago
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
First Approval in Japan for the KEYTRUDA Plus LENVIMA Combination KENILWORTH, N.J. & TOKYO--(BUSINESS WIRE)--$MRK…
4 years ago